


CLARK et al.  
Appl. No. 10/576,095  
Atty. Ref.: 620-432  
Amendment  
October 17, 2008

**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

1. (Currently Amended) A compound of formula (I):



or a salt, solvate or [[and]] chemically protected form thereof, wherein:

~~one of R<sup>2</sup> and R<sup>5</sup> is:~~

~~(i) H or an optionally substituted C<sub>1-4</sub> alkyl group; or~~

~~(ii) an optionally substituted C<sub>5-7</sub> aryl; and the other of R<sup>2</sup> and R<sup>5</sup> is the other group;~~

either

R<sup>2</sup> is H or an optionally substituted C<sub>1-4</sub> alkyl group and R<sup>5</sup> is an optionally substituted C<sub>5-7</sub> aryl; or

R<sup>5</sup> is H or an optionally substituted C<sub>1-4</sub> alkyl group and R<sup>2</sup> is an optionally substituted C<sub>5-7</sub> aryl;

m and n can be 0 or 1, and m + n = 1 or 2

R<sup>N</sup> is H or optionally substituted C<sub>1-4</sub> alkyl

R<sup>3</sup> is either:

[(i)] carboxy or tetrazole-5-yl

CLARK et al.

Appl. No. 10/576,095


Atty. Ref.: 620-432

Amendment


October 17, 2008

with the proviso that the compound in which R<sup>3</sup> is carboxy, n is 0, m is 1, R<sup>N</sup> is H,  
R<sup>2</sup> is methyl and R<sup>5</sup> is phenyl is excluded;

(ii) — a group of formula (III):



(iii) — a group of formula (III):



wherein R is optionally substituted C<sub>1-7</sub> alkyl, C<sub>5-20</sub> aryl, or NR<sup>N3</sup>R<sup>N4</sup>, where R<sup>N3</sup>  
and R<sup>N4</sup> are independently selected from optionally substituted C<sub>1-4</sub> alkyl; or

(iv) — tetrazol-5-yl.

2. (Currently Amended) A compound according to claim 1, wherein R<sup>5</sup> is  
[[the]]an optionally substituted C<sub>5-7</sub> aryl group and R<sup>2</sup> is H or the optionally substituted  
C<sub>1-4</sub> alkyl group.

3. (Original) A compound according to claim 2, wherein R<sup>2</sup> is selected from H or  
an optionally substituted C<sub>1-3</sub> alkyl group.

4. (Original) A compound according to claim 3, wherein R<sup>2</sup> is a methyl group.

5. (Previously Presented) A compound according to claim 2, wherein R<sup>5</sup> is a C<sub>6</sub>  
aryl group.

CLARK et al.  
Appl. No. 10/576,095  
Atty. Ref.: 620-432  
Amendment  
October 17, 2008

6. (Currently Amended) A compound according to claim 5, wherein R<sup>5</sup> is preferably phenyl.

7. (Currently Amended) A compound according to claim 1 wherein the C<sub>5-7</sub> aryl group of R<sup>2</sup> and R<sup>5</sup> is substituted by substituents selected from C<sub>1-7</sub> alkoxy groups.

Claim 8. (Canceled)

Claim 9. (Canceled)

Claim 10. (Canceled)

11. (Previously Presented) A compound according to claim 1, wherein n + m = 1.

12. (Original) A compound according to claim 11, wherein n is 0 and m is 1.

13. (Previously Presented) A compound according to claim 1, wherein R<sup>N</sup> is H or methyl.

14. (Currently Amended) [[The use]] A method of treating a primary headache disorder comprising administering to a patient in need of treatment an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in a method of therapy.

15. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

Claim 16. (Canceled)

Claim 17. (Canceled)

CLARK et al.  
Appl. No. 10/576,095  
Atty. Ref.: 620-432  
Amendment  
October 17, 2008

18. (Currently Amended) The [[use]] method according to claim [[17, ]]14  
wherein the primary headache disorder is a migraine.